This clinical study will move the BT Test forward in its FDA approval as first a supplementary and then a stand-alone screening tool for early breast cancer detection. With fewer false negative and false positive diagnoses, this cost-effective blood test may not only offer vastly superior early-detection capabilities in routine examinations, but may also help patients avoid unnecessary needle biopsies. |
We expect the results of this clinical study to demonstrate an even higher level of accuracy than either film or digital mammography. |
We expect the results of this clinical study to demonstrate an even higher level of accuracy than either film or digital mammography. With this greatly improved diagnostic accuracy, the BT Test will ultimately become a critical tool in detecting breast cancer without the discomfort and inconvenience of a mammogram. |